Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.
2.

Pegasparaginase: where do we stand?

Zeidan A, Wang ES, Wetzler M.

Expert Opin Biol Ther. 2009 Jan;9(1):111-9. doi: 10.1517/14712590802586058 . Review.

PMID:
19063697
3.

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.

Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH.

Cancer. 2011 Jan 15;117(2):238-49. doi: 10.1002/cncr.25489. Epub 2010 Sep 7. Review.

4.

Use of L-asparaginase in childhood ALL.

Müller HJ, Boos J.

Crit Rev Oncol Hematol. 1998 Aug;28(2):97-113. Review.

PMID:
9768345
5.
6.

Pegaspargase: an alternative?

Holle LM.

Ann Pharmacother. 1997 May;31(5):616-24. Review.

PMID:
9161659
7.

Optimizing asparaginase therapy for acute lymphoblastic leukemia.

Rizzari C, Conter V, Starý J, Colombini A, Moericke A, Schrappe M.

Curr Opin Oncol. 2013 Mar;25 Suppl 1:S1-9. doi: 10.1097/CCO.0b013e32835d7d85. Review.

PMID:
23380829
8.

PEG-asparaginase.

Fu CH, Sakamoto KM.

Expert Opin Pharmacother. 2007 Aug;8(12):1977-84. Review.

PMID:
17696798
9.

Erwinia asparaginase in pediatric acute lymphoblastic leukemia.

Salzer W, Seibel N, Smith M.

Expert Opin Biol Ther. 2012 Oct;12(10):1407-14. doi: 10.1517/14712598.2012.718327. Epub 2012 Sep 4. Review.

PMID:
22946493
10.
11.

[Update on L-asparaginase treatment in paediatrics].

Moscardó Guilleme C, Fernández Delgado R, Sevilla Navarro J, Astigarraga Aguirre I, Rives Solà S, Sánchez de Toledo Codina J, Fuster Soler JL, Parra Ramirez L, Molina Garicaño J, González Martínez B, Madero López L.

An Pediatr (Barc). 2013 Nov;79(5):329.e1-329.e11. doi: 10.1016/j.anpedi.2013.03.015. Epub 2013 May 31. Review. Spanish.

12.

Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.

Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP.

Ann N Y Acad Sci. 2014 Nov;1329:81-92. doi: 10.1111/nyas.12496. Epub 2014 Aug 5. Review.

13.

[Advances on the role of pegaspargase in the treatment of childhood leukemia].

Liu L, Xie XT.

Zhongguo Dang Dai Er Ke Za Zhi. 2014 Feb;16(2):155-60. Review. Chinese.

14.

How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.

Burke MJ.

Future Oncol. 2014 Dec;10(16):2615-27. doi: 10.2217/fon.14.138. Review.

15.

Peg-asparaginase for acute lymphoblastic leukemia.

Rytting M.

Expert Opin Biol Ther. 2010 May;10(5):833-9. doi: 10.1517/14712591003769808. Review.

PMID:
20345338
16.

Pegaspargase: a review of clinical studies.

Graham ML.

Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302. Review.

PMID:
14499708
17.

[Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].

Thomas X, Cannas G, Chelghoum Y, Gougounon A.

Bull Cancer. 2010 Sep;97(9):1105-17. doi: 10.1684/bdc.2010.1168. Review. French.

18.

Asparaginase revisited.

van den Berg H.

Leuk Lymphoma. 2011 Feb;52(2):168-78. doi: 10.3109/10428194.2010.537796. Review.

PMID:
21281233
19.

Asparaginase pharmacokinetics and implications of therapeutic drug monitoring.

Asselin B, Rizzari C.

Leuk Lymphoma. 2015;56(8):2273-80. doi: 10.3109/10428194.2014.1003056. Epub 2015 Mar 11. Review.

20.

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia.

Egler RA, Ahuja SP, Matloub Y.

J Pharmacol Pharmacother. 2016 Apr-Jun;7(2):62-71. doi: 10.4103/0976-500X.184769. Review.

Supplemental Content

Support Center